Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy?

American Heart Journal

Volumn 138, Issue 3 I, 1999, Pages 456-459

  Morimoto, S I ^a   Shimizu, K ^a   Yamada, K ^a   Hiramitsu, S ^a   Hishida, H ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; FEMALE; HEART DILATATION; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032843803     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70147-X     Document Type: Article

References (6)

1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
2. Engalmeier RS, O'Connell JB, Walsh R, Rad N,Scanlon PJ,Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72:536-46.
3. Anderson JL, Luts JR, Gilbert EM, Sorenson SG Yanowits FG, Menlove RL, et al. A randomized trial of low-dose B-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-5.
4. Yamada K, Morimoto S, Hiramitsu S. Indications for β-blockade therapy in dilated cardiomyopathy. Prognosis and treatment of cardiomyopathies and myocarditis. Tokyo: University of Tokyo Press; 1994. p. 169-74.
5. Kagiya T, Hori M, Fukunami M, Hoki N, Iwakura T, Kurihara T, et al. Role of β-adrenergic receptors in β-blocker therapy for chronic heart failure in patients with dilated cardiomyopathy [abstract]. Circulation 1987;76(Suppl IV):308.
6. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.